Skip to Content

Join the 'Liposarcoma' group to help and get support from people like you.

Liposarcoma News

Drug Combo Shows Promise Against Some Soft Tissue Tumors

Posted 9 days ago by Drugs.com

FRIDAY, Dec. 2, 2016 – Using a new cancer drug with an existing one appears to work against soft tissue sarcoma cancers, a new study indicates. These cancers of soft tissues such as fat, muscles, blood vessels, tendons and ligaments are rare, but difficult to treat if they are advanced and have spread to other parts of the body, the researchers said. "Soft tissue sarcomas represent a rare group of malignant tumors. Despite the use of surgery, radiotherapy and chemotherapy to treat the tumor in the localized region in which it started, up to 40 percent of patients will develop recurrence with cancer cells spreading to other parts of the body," said researcher Antoine Italiano. He heads the early phase trials and sarcoma units at Institut Bergonie in Bordeaux, France. His study found that the combination of a new cancer drug called GDC-0575 with the existing cancer drug gemcitabine ... Read more

Related support groups: Cancer, Gemzar, Gemcitabine, Soft Tissue Sarcoma, Dermatofibrosarcoma Protuberans, Liposarcoma, Kaposi's Sarcoma, Rhabdomyosarcoma

Lartruvo (olaratumab) Approved for Soft-Tissue Cancers

Posted 19 Oct 2016 by Drugs.com

WEDNESDAY, Oct. 19, 2016 – Lartruvo (olaratumab) has been approved by the U.S. Food and Drug Administration to treat adults with certain soft-tissue sarcomas, cancers that develop in areas such as the muscles, fat, blood vessels and tendons. Lartruvo has been sanctioned for use with the chemotherapy drug doxorubicin in cases that cannot be treated with radiation or surgery, the FDA said Wednesday in a news release. More than 12,000 new cases of soft-tissue sarcoma are projected to be diagnosed this year and nearly 5,000 people are likely to die from the disease, the agency said, citing estimates from the U.S. National Cancer Institute. Lartruvo is designed to block cell receptors that fuel tumor growth, the FDA said. The drug was evaluated in clinical trials involving 133 people with soft-tissue carcinomas. Average survival among people who took Lartruvo and doxorubicin was 8.2 months, ... Read more

Related support groups: Cancer, Adriamycin, Soft Tissue Sarcoma, Doxorubicin, Dermatofibrosarcoma Protuberans, Rhabdomyosarcoma, Liposarcoma, Adriamycin RDF, Kaposi's Sarcoma, Adriamycin PFS

FDA Approves Halaven (eribulin mesylate) for the Treatment of Liposarcoma

Posted 28 Jan 2016 by Drugs.com

January 28, 2016 – The U.S. Food and Drug Administration today approved Halaven (eribulin mesylate), a type of chemotherapy, for the treatment of liposarcoma (a specific type of soft tissue sarcoma) that cannot be removed by surgery (unresectable) or is advanced (metastatic). This treatment is approved for patients who received prior chemotherapy that contained an anthracycline drug. “Halaven is the first drug approved for patients with liposarcoma that has demonstrated an improvement in survival time,” said Richard Pazdur, M.D., director of the Office of Hematology and Oncology Products in the FDA’s Center for Drug Evaluation and Research. “The clinical trial data the FDA reviewed indicates that Halaven increased overall survival by approximately seven months, offering patients a clinically meaningful drug.” Soft tissue sarcoma (STS) is a disease in which cancer cells form in the sof ... Read more

Related support groups: Soft Tissue Sarcoma, Eribulin, Halaven, Liposarcoma

Ask a Question

Further Information

Related Condition Support Groups

Soft Tissue Sarcoma

Related Drug Support Groups

eribulin, Halaven